ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,328Medicare Part D Prescriptions Filled, Including Refills

Rank: 101 out of 617

$714K Total Retail Price of All Prescriptions

Rank: 27 out of 617

477 Patients Receiving at Least One Drug in Part D
66%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

16% of this provider’s 477 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

23% of this provider’s 477 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

2% of this provider’s 6,786 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$69 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 479 356 1 1
HYDROCODONE-ACETAMINOPHEN 427 231 S3 2 8
OMEPRAZOLE 410 269 3 3
AMLODIPINE BESYLATE 287 241 4 6
SIMVASTATIN 252 190 5 2
METOPROLOL SUCCINATE 220 156 6 12
FUROSEMIDE 200 145 7 4
HYDROCHLOROTHIAZIDE 189 158 8 13
METOPROLOL TARTRATE 185 139 9 11
ZOLPIDEM TARTRATE 179 99 10 23
GLIMEPIRIDE 140 107 11 33
ATORVASTATIN CALCIUM 135 108 12 14
METFORMIN HCL 132 107 13 9
LISINOPRIL 131 105 14 5
PROAIR HFA 114 48 15 75
CITALOPRAM HBR 114 84 15 18
OXYCODONE HCL-ACETAMINOPHEN 114 46 S2 15 134
PANTOPRAZOLE SODIUM 113 100 18 37
GABAPENTIN 111 39 19 16
CYCLOBENZAPRINE HCL 98 33 R 20 74
WARFARIN SODIUM 94 77 21 7
POTASSIUM CHLORIDE 86 71 22 10
MELOXICAM 85 53 23 24
CRESTOR 83 70 24 28
TRAZODONE HCL 81 22 25 51
CLOPIDOGREL 77 57 26 53
ATENOLOL 72 55 27 17
DICLOFENAC SODIUM 72 43 27 98
AZITHROMYCIN 72 42 27 70
SYNTHROID 72 72 27 59
COMBIVENT 69 61 31 187
NEXIUM 69 47 31 43
TRAMADOL HCL 69 33 31 15
FENTANYL 66 32 S2 34 45
RAMIPRIL 64 48 35 67
IBUPROFEN 63 42 36 140
CARVEDILOL 63 57 36 19
DIOVAN 62 42 38 41
ESCITALOPRAM OXALATE 61 22 39 65
LYRICA 60 12 40 92
ADVAIR DISKUS 60 20 40 38
PAROXETINE HCL 60 51 40 62
ALENDRONATE SODIUM 59 53 43 25
PREDNISONE 58 45 44 31
LAMOTRIGINE 57 45 45 154
PLAVIX 57 46 45 86
CLONIDINE HCL 54 38 47 55
DIGOXIN 54 45 47 48
CIPROFLOXACIN HCL 54 41 47 60
DONEPEZIL HCL 53 53 50 30
ABILIFY 51 22 51 131
SPIRONOLACTONE 51 30 51 42
OXYCODONE HCL 51 33 S2 51 130
CYMBALTA 50 11 54 49
BACLOFEN 50 0 54 146
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 31, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.